IL13RA2 and cancer: Further, when we down-regulated IL-13R α2 expression in the cancer cells via siRNA treatment, they lost sensitivity to Pep-1-Phor21, confirming that this hybrid peptide kills the cancer cells by targeting IL-13Rα2 (Figure S1).